SILOFAST D 8MG CAPSULE

What is SILOFAST D 8MG CAPSULE?

SILOFAST D 8MG CAPSULE is a prescription medication designed to manage benign prostatic hyperplasia (BPH), a common condition in aging men where the prostate gland enlarges and obstructs normal urinary flow. It contains two active ingredients: Dutasteride, a 5-alpha reductase inhibitor that reduces prostate size by lowering dihydrotestosterone (DHT) levels, and Silodosin, an alpha-1 blocker that relaxes prostate and bladder neck muscles to improve urine flow. This dual mechanism targets both the structural and functional aspects of BPH, offering comprehensive symptom relief.

Key features

• Dual-Action Formula — Combines Dutasteride and Silodosin for comprehensive BPH treatment.
• Improves Urinary Flow — Relaxes smooth muscles in the prostate and bladder neck.
• Reduces Prostate Size — Dutasteride inhibits DHT production, shrinking the enlarged gland over time.
• Lowers Surgery Risk — Clinically shown to reduce the need for BPH-related surgical intervention.
• Once-Daily Dosing — Convenient regimen enhances patient adherence.
• Targets Acute Retention — Helps prevent sudden inability to urinate, a medical emergency in BPH patients.
• Prescription-Based — Ensures medical supervision for safe and effective use.

Who is SILOFAST D 8MG CAPSULE for?

This capsule is intended for adult men diagnosed with moderate to severe BPH symptoms, including frequent urination, weak stream, urgency, or nocturia. It's ideal for those seeking both symptomatic relief and long-term reduction in prostate volume. Not suitable for women or children. Patients with liver impairment or allergy to its components should avoid use.

How does SILOFAST D 8MG CAPSULE compare?

Compared to single-agent therapies like standard alpha-blockers or 5-alpha reductase inhibitors alone, SILOFAST D 8MG offers superior symptom control and disease modification. It outperforms monotherapies in reducing prostate size and preventing complications like urinary retention. While similar to other combination therapies, its specific dosing of 8mg Silodosin with Dutasteride provides targeted efficacy with a well-documented safety profile in clinical settings.